Repligen Corp (NAS:RGEN)
$ 166.895 -4.885 (-2.84%) Market Cap: 9.33 Bil Enterprise Value: 9.56 Bil PE Ratio: 667.58 PB Ratio: 4.73 GF Score: 93/100

Repligen Corp at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 05:30PM GMT
Release Date Price: $164.23 (-4.97%)
Brandon Couillard
Jefferies LLC, Research Division - Equity Analyst

All right. Good afternoon, everybody. Thanks for joining us. We're going to get started. Welcome to the Jefferies 2023 Global Healthcare Conference. I'm Brandon Couillard, I cover the life sciences space. Very happy to have Repligen with us back at the conference this year. And here to share an update with us, Jon Snodgres, CFO. Jon?

Jon K. Snodgres
Repligen Corporation - CFO

Well, thank you, Brandon, and good day, everybody. Pleasure today to be here to give you an update on Repligen, and how we continue to move technology forward in our industry to become a leading company in bioprocessing. Sorry that we have to do it right after lunch. So hopefully, everybody has got a little bit of energy to get through this. No food comas here.

Anyway, really quickly, I'll start with a company overview, talk a little bit about how we've developed our portfolio and our customer base over the years, and we'll get into some of the more detailed stuff on technology.

So I think this chart

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot